• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1260731 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type3 E: c# z; }' Y4 j# I) X
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
" B) a3 F4 c/ _% C+ Author Affiliations, ?/ }- W. H; J5 z6 o! X+ D
. H7 D% I% k- e3 u* j; s
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
8 Q8 M- G, U+ A3 B& I2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan . v; k9 B! X( t7 v$ w
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
; }" |) z" z2 I) X% O* C. |4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) u+ h9 u# v' Z% @/ k4 G9 d
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
; `3 v9 o* J& w: O: E6 l5 C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
+ @4 s: S* z: T8 k6 c6 Y6 ]7Kinki University School of Medicine, Osaka 589-8511, Japan
- q1 L& [  v8 G/ S3 }2 E8Izumi Municipal Hospital, Osaka 594-0071, Japan
3 K) `4 A8 h. \1 g, N6 S8 V: B9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
* q' \% L* k. W! e) b* xCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp . C! f  @$ W* D
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. + l! g* t) w; U$ C& p" s& [7 W
$ N9 k; f+ e9 u/ U7 A$ W" T
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
; o+ ?) r1 z- v* p" ]; ]
7 X% {" `, F+ qAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
' \+ e# l3 s: B# e! |3 Q; Y: _; u, V2 T" E
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
# ?/ i4 W: w5 A0 g% C; J1 Y) S0 _  g
Published online on: Thursday, December 1, 2011 9 {4 o% u, O+ u7 L* m2 N) [' K

1 A: Z4 g2 E7 n4 d, uDoi: 10.3892/ol.2011.507 / ?6 g3 _1 s" w8 T

9 N4 O: C  H  j7 o  rPages: 405-410 0 L- D9 [( S2 G$ H$ q: o. Q

# V* ^" h" Q+ @" OAbstract:: v* q1 r# p. Z8 Q4 [$ |6 c0 |) [
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
& D) d: F4 N2 Q7 ?) C$ C0 s % @( D; G* \2 c5 p* S* k  S6 V
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population5 c6 N$ s  }4 p# r4 l! r
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 9 ~' v) e" J8 g6 S8 y# A
+ Author Affiliations% E1 i0 W: w9 p9 ]/ z
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 9 e6 d8 n/ F9 N: ~& {& ]
2Department of Thoracic Surgery, Kyoto University, Kyoto
+ _" @" t& w' V+ u: e9 x- a3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan . s) C1 e' Z8 c# H
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
. {4 c3 |$ x7 N7 j& bReceived September 3, 2010.
/ r$ b4 A; j3 S. y" X- KRevision received November 11, 2010.
7 n3 l0 B+ a. Y. lAccepted November 17, 2010.
& z; P. L, u/ w, _* y9 AAbstract
, Z, m  ^! Q; R9 R; z7 P9 _Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
+ t' r1 J$ E( S" H8 k& V4 E8 JPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. : N% M+ `( H$ e. a
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
6 V9 O: s- u, ]1 y& J9 KConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. 2 H0 Z) p/ D3 Y0 a) X8 g+ u6 f
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。) y# }6 V1 b- _+ `$ e
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?, {8 n' h* s7 {
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
3 |% g; r0 E! f% T- Lhttp://clinicaltrials.gov/ct2/show/NCT01523587* F- b# y* O$ h6 y
8 j# ^; p; k0 c
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC: t) D5 N) ~. J) B$ ~9 |
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 * W, I  E3 ~& g; M

' L' Z. u& |4 u3 |从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。, a5 v3 g7 x- _3 g5 ]
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
4 ^$ ^6 G. W9 L4 H/ g+ W从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。4 m- ~. W* z9 \# E! E+ y4 h1 w
至今为止,未出 ...

# [" E# Z* m( F5 u+ v没有副作用是第一追求,效果显著是第二追求。9 @+ D" D: h% A7 h# B4 w
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表